BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:14 PM
 | 
Sep 04, 2012
 |  BC Extra  |  Company News

Approvals for Pfizer's bosutinib, axitinib

Pfizer Inc. (NYSE:PFE) announced approvals Tuesday for two cancer drugs: Bosulif bosutinib in the U.S. and Inlyta axitinib in Europe. FDA approved Bosulif to...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >